Takashi Fukuda
Corporate Officer/Principal at SANKYO CO., LTD.
Profile
Takashi Fukuda has held the following positions in his career: Director & Senior Managing Director at ARK Resource Co. Ltd.
and Executive Officer & Deputy GM-Products at Sankyo Co., Ltd.
Takashi Fukuda active positions
Companies | Position | Start |
---|---|---|
SANKYO CO., LTD. | Corporate Officer/Principal | 2010-10-28 |
ARK Resource Co. Ltd.
ARK Resource Co. Ltd. BiotechnologyHealth Technology ARK Resource Co. Ltd. is a Japanese company that specializes in the manufacturing of monoclonal and polyclonal antibodies, fertilized eggs in mouse/rats, and culture used for reproductive engineering. ARK Resource Co. was founded in 1966 and is based in Kumamoto, Japan, with headquarters located at 383-2 Nakahara-cho, Nishi-ku, Kumamoto-shi, Kumamoto. The company offers a wide range of services from units to g units, including the supply of mouse monoclonal antibodies by ascelonus method and culture method. The company also provides a quick diagnostic genetic modified animal breeding colony by the service introduction pcr method, performing homo / hetero / wild type screening (geno typing). The company can identify specific disease bacteria in biological samples and culture cells. | Director/Board Member | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
SANKYO CO., LTD. | Producer Manufacturing |
Private companies | 1 |
---|---|
ARK Resource Co. Ltd.
ARK Resource Co. Ltd. BiotechnologyHealth Technology ARK Resource Co. Ltd. is a Japanese company that specializes in the manufacturing of monoclonal and polyclonal antibodies, fertilized eggs in mouse/rats, and culture used for reproductive engineering. ARK Resource Co. was founded in 1966 and is based in Kumamoto, Japan, with headquarters located at 383-2 Nakahara-cho, Nishi-ku, Kumamoto-shi, Kumamoto. The company offers a wide range of services from units to g units, including the supply of mouse monoclonal antibodies by ascelonus method and culture method. The company also provides a quick diagnostic genetic modified animal breeding colony by the service introduction pcr method, performing homo / hetero / wild type screening (geno typing). The company can identify specific disease bacteria in biological samples and culture cells. | Health Technology |
- Stock Market
- Insiders
- Takashi Fukuda